Literature DB >> 20465556

Appropriate antenatal corticosteroid use in women at risk for preterm birth before 34 weeks of gestation.

R Mahony1, A McKeating, T Murphy, F McAuliffe, C O'Herlihy, M Foley.   

Abstract

OBJECTIVE: To determine the utilisation of antenatal corticosteroid administration in women presenting at risk of preterm birth (PTB) in a centre where tocolytics are not prescribed.
DESIGN: A prospective cohort study.
SETTING: Tertiary referral centre, Dublin, Ireland. POPULATION: Four hundred and fourteen consecutive women presenting at risk of PTB.
METHODS: Clinical details were collated prospectively on all booked patients who presented at risk of PTB (i.e. at <34 weeks of gestation) during 2008. MAIN OUTCOME MEASURE: Rate of administration of antenatal corticosteroids in PTB.
RESULTS: Of 8985 deliveries, 414 women (5%) presented at <34 weeks of gestation with a clinical potential for PTB, of whom 277 (67%) received antenatal corticosteroids. Amongst women delivering at <34 weeks of gestation, 93% (80/86) received any corticosteroids and 76% (65/86) received a complete course. The ratio of women given a complete course of corticosteroids to the number who actually delivered before 34 weeks of gestation was 4:1 overall. Analysis by indication for PTB revealed this ratio to be 15:1 in suspected preterm labour (PTL), 8:1 in antepartum haemorrhage (APH), and 2:1 in both preterm prelabour rupture of membranes (PPROM) and medically indicated PTB (MIPTB). Seven of ten multiparae (70%) who delivered prematurely during the study period following PTL had a history of previous PTL before 34 weeks of gestation.
CONCLUSION: The ratio of maternal antenatal corticosteroid administration for potential versus actual PTB at <34 weeks of gestation was high in categories such as PTL and substantial APH, whereas selection in PPROM and MIPTB approached 100%. There should be a low threshold for single course therapy for women with prior PTL before 34 weeks of gestation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20465556     DOI: 10.1111/j.1471-0528.2010.02590.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  5 in total

Review 1.  Antenatal corticosteroids in the management of preterm birth: are we back where we started?

Authors:  Clarissa Bonanno; Ronald J Wapner
Journal:  Obstet Gynecol Clin North Am       Date:  2012-03       Impact factor: 2.844

2.  Prediction of neonatal respiratory morbidity by quantitative ultrasound lung texture analysis: a multicenter study.

Authors:  Montse Palacio; Elisenda Bonet-Carne; Teresa Cobo; Alvaro Perez-Moreno; Joan Sabrià; Jute Richter; Marian Kacerovsky; Bo Jacobsson; Raúl A García-Posada; Fernando Bugatto; Ramon Santisteve; Àngels Vives; Mauro Parra-Cordero; Edgar Hernandez-Andrade; José Luis Bartha; Pilar Carretero-Lucena; Kai Lit Tan; Rogelio Cruz-Martínez; Minke Burke; Suseela Vavilala; Igor Iruretagoyena; Juan Luis Delgado; Mauro Schenone; Josep Vilanova; Francesc Botet; George S H Yeo; Jon Hyett; Jan Deprest; Roberto Romero; Eduard Gratacos
Journal:  Am J Obstet Gynecol       Date:  2017-03-23       Impact factor: 8.661

3.  Discordance in Antenatal Corticosteroid Use and Resuscitation Following Extremely Preterm Birth.

Authors:  Matthew A Rysavy; Edward F Bell; Jay D Iams; Waldemar A Carlo; Lei Li; Brian M Mercer; Susan R Hintz; Barbara J Stoll; Betty R Vohr; Seetha Shankaran; Michele C Walsh; Jane E Brumbaugh; Tarah T Colaizy; Abhik Das; Rosemary D Higgins
Journal:  J Pediatr       Date:  2019-02-06       Impact factor: 4.406

4.  Prenatal steroid administration leads to adult pericardial and hepatic steatosis in male baboons.

Authors:  A H Kuo; J Li; C Li; H F Huber; M Schwab; P W Nathanielsz; G D Clarke
Journal:  Int J Obes (Lond)       Date:  2017-03-24       Impact factor: 5.095

5.  Timing of delivery in a high-risk obstetric population: a clinical prediction model.

Authors:  Dane A De Silva; Sarka Lisonkova; Peter von Dadelszen; Anne R Synnes; Laura A Magee
Journal:  BMC Pregnancy Childbirth       Date:  2017-06-29       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.